Should a patient who has been taking bupropion (Wellbutrin) 150 mg daily for two years continue the medication?

Should the Patient Continue Wellbutrin 150 mg After 2 Years?

Yes, the patient should continue bupropion (Wellbutrin) 150 mg, as maintenance therapy for 4-9 months is recommended after initial response, and for patients with recurrent depression (which 2 years of treatment suggests), even longer duration may be beneficial to prevent relapse.

Rationale for Continuation

The decision to continue antidepressant therapy depends on several key factors:

Duration of Treatment Guidelines

For first-episode major depressive disorder, the American College of Physicians recommends continuing treatment for 4 to 9 months after satisfactory response 1. However, for patients with 2 or more episodes of depression, an even longer duration of therapy may be beneficial 1.

The fact that this patient has been on treatment for 2 years suggests either:

• A first episode requiring extended maintenance, or
• Recurrent depression requiring long-term prophylaxis

Evidence for Long-Term Efficacy

A pivotal randomized withdrawal trial demonstrated that bupropion sustained-release significantly reduces relapse rates when continued for up to 44 weeks 2. In this study:

• Patients who responded to 8 weeks of bupropion 300 mg daily were randomized to continue bupropion or switch to placebo
• Bupropion-treated patients experienced significantly lower relapse rates over 44 weeks compared to placebo 2
• The relapse was defined as the investigator's judgment that drug treatment was needed for worsening depressive symptoms 2

Additional research confirms that continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression for up to 44 weeks 3.

Clinical Decision Algorithm

Step 1: Assess Current Clinical Status

• Is the patient currently in remission with good symptom control?
  • If YES → Continue to Step 2
  • If NO → Consider dose optimization (standard dose is 300 mg/day, not 150 mg) 2

Step 2: Determine Depression History

• Is this the patient's first episode or recurrent depression?
  • First episode: Consider continuation for at least 4-9 months total from initial response 1
  • Recurrent (≥2 episodes): Strongly consider indefinite maintenance therapy 1
  • Unknown history after 2 years of treatment suggests likely recurrent or chronic course

Step 3: Evaluate Risk-Benefit

• Are there significant adverse effects?
  • Common side effects: dry mouth, insomnia (dose-related) 4
  • Serious concerns: seizure risk (0.10% at therapeutic doses ≤300 mg/day) 5
  • If well-tolerated for 2 years → favorable risk-benefit for continuation

Step 4: Consider Dose Adequacy

Important caveat: The patient is on 150 mg daily, which is below the standard therapeutic dose:

• Standard dosing: 150 mg twice daily (300 mg/day total) 2
• The 450 mg dose showed superior efficacy in controlled trials 2
• If symptoms are well-controlled on 150 mg, this may be adequate, but if residual symptoms exist, dose escalation should be considered

Contraindications to Continuation

Discontinue bupropion if:

• Seizure disorder develops
• Brain metastases or structural brain lesions
• Concurrent MAO inhibitor use
• Eating disorder diagnosis
• Closed-angle glaucoma 6
• Pregnancy (relative contraindication - requires risk-benefit assessment) 7

Monitoring Recommendations

While continuing treatment:

• Assess patient status, therapeutic response, and adverse effects regularly (at least every 1-2 weeks initially, then as clinically indicated) 1
• Monitor for neuropsychiatric symptoms: agitation, depression worsening, suicidal ideation 6, 4
• Monitor blood pressure if using with other medications 8

Discontinuation Strategy (If Appropriate)

If deciding to discontinue after thorough assessment:

• Taper over 10-14 days to limit withdrawal symptoms 9
• After 9 months of treatment, dosage reduction can be used to reassess the need to medicate 9
• Close monitoring during and after discontinuation for relapse signs

Special Considerations

Advantages of once-daily formulation (XL): If the patient is on twice-daily dosing (SR formulation), consider switching to once-daily XL formulation, as adherence and persistence are significantly better with once-daily bupropion XL compared to twice-daily SR 10, 11.

Bottom line: Given 2 years of treatment, the patient likely has recurrent or chronic depression requiring long-term maintenance. Continue bupropion indefinitely unless contraindications develop or the patient experiences significant adverse effects, with periodic reassessment of ongoing need.